FOR YEARS, ALZHEIMER'S CONFERENCES WERE like the obituary pages in the local newspaper: It's where clinicians and researchers in the field went to find out the names of the latest promising drugs to die. Between 1998 and 2017 alone, 146 clinical trials of new Alzheimer's drugs failed.
So when Randall Bateman showed up outside a restaurant in Bar Harbor, Maine, one evening in the fall of 2022 during an industry confab and announced to a couple of tables full of his colleagues drinking on the patio that he had something important to share with them, no one was prepared for what came next.
Bateman, a neurologist and Alzheimer's researcher at the Washington University School of Medicine in St. Louis, told them he had just received a phone call from his contact at the drug company running the trials of lecanemab, an experimental drug designed to facilitate the removal of the toxic plaques in the brain associated with the disease. The results, set for public release the following morning, were in: In a study of 1,800 Alzheimer's patients over 18 months, the treatment had reduced the rate of cognitive decline by close to 30 percent.
There was a stunned silence and some skeptical questions. Then the table erupted in applause.
"It's all anybody talked about for the rest of the meeting," says Bateman. "The agenda was blown. Nobody was paying attention to what we should have been doing. It's reenergized, recharged, everything."
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Can Alternative Therapies Treat Cancer?
Doctor and breast cancer survivor Liz O'Riordan addresses misinformation around managing the disease
Falling for Romance
A new book, Nora Ephron at the Movies, celebrates the writer/director best known for her iconic rom-coms and strong female characters
Cracking the Norse Code
Walrus DNA has shown that Vikings were likely the first to have encountered Indigenous North Americans
Monumental Shift
The discovery of 165-million-year-old crystals Easter Island has upended the longheld notion of how the Earth's \"conveyor belt\" moves
'OUR FOREIGN POLICY AND DOMESTIC REFORMS ARE TWO SIDES OF THE SAME COIN'
It is a well-known fact across the globe that the North Korean regime is irrational and unpredictable, but we have been consistent in strengthening our defense posture against the threat from North Korea since the Korean War, and I believe that their conventional capability is much inferior to that of the Korean military.
'They Read My Eulogy As I Lay in an Open Grave'
Like Paris Hilton, Natasia Pelowski claims she was subjected to abuse at a teenage therapy program
Russian Economy Faces 'Burnout
Vladimir Putin admits difficulties” as the country’s key interest rate reaches a historic high
China's 'Silent Chemical War'
The U.S. must investigate Beijing's role in the manufacturing of fentanyl that is killing Americans, says one mom whose daughter died after accidentally taking the illicit substance
HARSH HEADWINDS
President Yoon Suk Yeol's BATTLE to reform a South Korea beset with structural problems under the specter of an increasingly aggressive neighbor to THE NORTH
Bridget Everett
BRIDGET EVERETT NEVER THOUGHT SHE'D BE THE LEAD OF A TV SHOW. \"I come from the downtown world in New York, a cabaret singer, and these things just don't happen, you don't find yourself with three seasons of HBO.
